Cisplatin plus gemcitabine for biliary tract cancer [2]

New England Journal of Medicine

Volumn 363, Issue 2, 2010, Pages 192-

  Hall, Ferris M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CISPLATIN PLUS GEMCITABINE; GEMCITABINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CLINICAL TRIAL; GALLBLADDER CANCER; HUMAN; LETTER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; BILIARY TRACT TUMOR; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CISPLATIN; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; HUMANS;

EID: 77954416814     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1005317     Document Type: Letter

References (2)

1. Cooke M. Cost consciousness in patient care - what is medical education's responsibility? N Engl J Med 2010;362:1253-5.
2. Wolpin BM, Mayer RJ. A step forward in the treatment of advanced biliary tract cancer. N Engl J Med 2010;362:1335-7.